Enzo Biochem (NYSE:ENZ) Now Covered by StockNews.com

Research analysts at StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Stock Up 3.5 %

Shares of ENZ stock opened at $1.18 on Friday. The stock has a 50-day moving average of $1.12 and a 200-day moving average of $1.14. Enzo Biochem has a one year low of $0.99 and a one year high of $1.50.

Institutional Trading of Enzo Biochem

A number of large investors have recently bought and sold shares of ENZ. Wittenberg Investment Management Inc. bought a new stake in Enzo Biochem during the 4th quarter worth approximately $95,000. Renaissance Technologies LLC lifted its holdings in Enzo Biochem by 2.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after purchasing an additional 64,417 shares during the last quarter. Finally, XTX Topco Ltd lifted its holdings in Enzo Biochem by 94.5% during the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 13,735 shares during the last quarter. 36.90% of the stock is owned by institutional investors.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.